WilmerHale recognizes its corporate responsibility to environmental stewardship.

Life Sciences

2014: Recognized both globally and nationally as a leading life sciences practice, WilmerHale has four decades of experience representing biotechnology, pharmaceutical and medical device companies at all stages of growth, as well as venture capitalists and investment banks. We have represented life sciences clients in venture financings, public offerings, mergers and acquisitions, and strategic alliances and collaborations; protected their innovations through patent prosecution and portfolio development; defended their interests in enterprise-critical patent litigation; and navigated regulatory issues vital to their success. The following is a selection of our recent life sciences transactions.
Counsel of Choice to Life Sciences Innovators
SERVING INDUSTRY LEADERS IN BIOTECHNOLOGY, PHARMACEUTICALS, MEDICAL DEVICES AND BEYOND

Mergers and Acquisitions/Strategic Alliances and Collaborations

- **Aralez Pharmaceuticals**
  - Acquired by **Eli Lilly**
  - $1,065,000,000
  - March 2014

- **Rempex Pharmaceuticals**
  - Acquired by **Cynosure**
  - $474,000,000
  - December 2013

- **Mitos murky**
  - Collaboration with **Novo Nordisk**
  - Licensing, clinical trial and manufacturing agreements
  - $32,400,000
  - March 2013

- **Tetraphase**
  - Collaboration with **Portola Pharmaceuticals**
  - $34,200,000
  - December 2013

- **Ophthotech**
  - Collaboration with **Pacific Biosciences**
  - $50,000,000
  - October 2013

- **Cereulan**
  - Mitochondria-related disease collaboration and acquisition option with **Astellas**
  - $125,120,000
  - December 2013

- **Biotherapeutics**
  - Collaboration with **GlaxoSmithKline**
  - Antibody discovery platform license
  - $43,000,000
  - November 2013

- **Biotherapeutics**
  - Collaboration with **Biogen Idec**
  - Antibody discovery platform license
  - $45,000,000
  - October 2013

Venture Capital Financings

- **Visterra**
  - First Round
  - $34,200,000
  - December 2013

- **Spark**
  - First Round
  - $50,000,000
  - December 2013

- **Aileron**
  - First Round
  - $30,000,000
  - November 2013

- **Cydan**
  - First Round
  - $26,000,000
  - March 2013

- **Editas**
  - First Round
  - $43,000,000
  - November 2013

Initial Public Offerings

- **uniQure**
  - Initial Public Offering of Common Stock
  - $93,100,000
  - February 2014

- **Epizyme**
  - Initial Public Offering of Common Stock
  - $88,700,000
  - June 2014

- **ConCERT**
  - Initial Public Offering of Common Stock
  - $93,100,000
  - February 2014

Follow-on Offerings

- **Merrimack**
  - Public Offering of Common Stock
  - $123,500,000
  - July 2013

- **DuRata**
  - Public Offering of Common Stock
  - $57,500,000
  - April 2013

- **Avec**
  - Public Offering of Common Stock
  - $341,913,000
  - February 2013

- **Pacira**
  - Public Offering of Common Stock
  - $25,000,000
  - December 2013
Life Sciences

2014: Recognized both globally and nationally as a leading life sciences practice, WilmerHale has four decades of experience representing biotechnology, pharmaceutical and medical device companies at all stages of growth, as well as venture capitalists and investment banks. We have represented life sciences clients in venture financings, public offerings, mergers and acquisitions, and strategic alliances and collaborations; protected their innovations through patent prosecution and portfolio development; defended their interests in enterprise-critical patent litigation; and navigated regulatory issues vital to their success. The following is a selection of our recent life sciences transactions.